Oyeon Cho1, Mison Chun2, Suk-Joon Chang3, Young-Taek Oh1, O Kyu Noh1. 1. Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Republic of Korea. 2. Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Republic of Korea chunm@ajou.ac.kr. 3. Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Republic of Korea.
Abstract
AIM: To investigate whether common terminology criteria for adverse events (CTCAE) grade 4 lymphopenia (<200 cells/μl) during concurrent chemoradiotherapy (CCRT) is relevant to poor survival. PATIENTS AND METHODS: We analyzed 124 patients with newly diagnosed Federation of Gynecology and Obstetrics (FIGO) stage I-III cervical cancer who received weekly cisplatin-based CCRT and brachytherapy using Kaplan-Meier curves and the Cox proportional hazard models. RESULTS: Grade 4 lymphopenia significantly predicted disease-specific survival (DSS) and progression-free survival (PFS) (adjusted hazard ratio (95% confidence interval (CI))=3.6 (1.37-9.44), p=0.009 and 3.28 (1.27-8.48), p=0.014, respectively). The 5-year DSS and 3-year PFS were significantly higher among patients with grade 2-3 lymphopenia (≥200 cells/μl) than among those with grade 4 lymphopenia (84.8% vs. 50.4%, p<0.001, and 80.7% vs. 50%, p=0.002, respectively). CONCLUSION: Severe lymphopenia during CCRT could predict poor survival. Copyright
AIM: To investigate whether common terminology criteria for adverse events (CTCAE) grade 4 lymphopenia (<200 cells/μl) during concurrent chemoradiotherapy (CCRT) is relevant to poor survival. PATIENTS AND METHODS: We analyzed 124 patients with newly diagnosed Federation of Gynecology and Obstetrics (FIGO) stage I-III cervical cancer who received weekly cisplatin-based CCRT and brachytherapy using Kaplan-Meier curves and the Cox proportional hazard models. RESULTS: Grade 4 lymphopenia significantly predicted disease-specific survival (DSS) and progression-free survival (PFS) (adjusted hazard ratio (95% confidence interval (CI))=3.6 (1.37-9.44), p=0.009 and 3.28 (1.27-8.48), p=0.014, respectively). The 5-year DSS and 3-year PFS were significantly higher among patients with grade 2-3 lymphopenia (≥200 cells/μl) than among those with grade 4 lymphopenia (84.8% vs. 50.4%, p<0.001, and 80.7% vs. 50%, p=0.002, respectively). CONCLUSION: Severe lymphopenia during CCRT could predict poor survival. Copyright
Authors: Grace Lee; Daniel W Kim; Vinayak Muralidhar; Devarati Mitra; Nora K Horick; Christine E Eyler; Theodore S Hong; Lorraine C Drapek; Jill N Allen; Lawrence S Blaszkowsky; Bruce Giantonio; Aparna R Parikh; David P Ryan; Jeffrey W Clark; Jennifer Y Wo Journal: Oncologist Date: 2020-09-12
Authors: Sweet Ping Ng; Houda Bahig; Amit Jethanandani; Courtney Pollard; Joel Berends; Erich M Sturgis; Faye M Johnson; Baher Elgohari; Hesham Elhalawani; David I Rosenthal; Heath D Skinner; G Brandon Gunn; Jack Phan; Steven J Frank; Abdallah S R Mohamed; Clifton D Fuller; Adam S Garden Journal: Radiother Oncol Date: 2020-01-10 Impact factor: 6.280
Authors: Radhe Mohan; Amy Y Liu; Paul D Brown; Anita Mahajan; Jeffrey Dinh; Caroline Chung; Sarah McAvoy; Mary Frances McAleer; Steven H Lin; Jing Li; Amol J Ghia; Cong Zhu; Erik P Sulman; John F de Groot; Amy B Heimberger; Susan L McGovern; Clemens Grassberger; Helen Shih; Susannah Ellsworth; David R Grosshans Journal: Neuro Oncol Date: 2021-02-25 Impact factor: 12.300
Authors: Alexander J Lin; Elizabeth Kidd; Farrokh Dehdashti; Barry A Siegel; Sasa Mutic; Premal H Thaker; Leslie S Massad; Matthew A Powell; David G Mutch; Stephanie Markovina; Julie Schwarz; Perry W Grigsby Journal: Int J Radiat Oncol Biol Phys Date: 2018-11-14 Impact factor: 7.038
Authors: Yasmin Hasan; Larissa Furtado; Ana Tergas; Nita Lee; Rebecca Brooks; Anne McCall; Daniel Golden; Shruti Jolly; Gini Fleming; Matthew Morrow; Kimberly Kraynyak; Albert Sylvester; Fauzia Arif; Matt Levin; David Schwartz; Jean Boyer; Jeffrey Skolnik; Mark Esser; Rakesh Kumar; Mark Bagarazzi; Ralph Weichselbaum; Michael Spiotto Journal: Int J Radiat Oncol Biol Phys Date: 2020-03-07 Impact factor: 7.038
Authors: Clemens Grassberger; Susannah G Ellsworth; Moses Q Wilks; Florence K Keane; Jay S Loeffler Journal: Nat Rev Clin Oncol Date: 2019-06-26 Impact factor: 66.675